Monitor upcoming Q2 earnings for profitability recovery as guided, and track early Lifyorli sales trajectory. Insider sales are minor and do not warrant action, but any acceleration in selling by C-suite would be a watch item.
CORT drugs
CORT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $51.42entry
- T+1 · 7mo ago +0.35%α +0.69% · $51.60
- T+5 · 6mo ago −0.72%α −3.07% · $51.05
- T+20 · 6mo ago +36.99%α +31.70% · $70.44
- T+60 · 4mo ago +83.18%α +80.11% · $94.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades represent only ~0.05% of market cap and are likely routine portfolio management, not a bearish signal. Q1 revenue grew 4.9% YoY to $164.9M, but the company reported a net loss of $31.8M vs net income of $20.5M in the prior year, driven by increased spending on the Lifyorli launch.
Key Financial Metrics
Key Facts
- CEO Belanoff sold 40,000 shares at ~$50.10 for $2.00M on May 1, 2026.
- CDO Guyer sold 20,000 shares at ~$51.83 for $1.04M on May 5, 2026 (also exercised options with no cash impact).
- Total insider sales of $3.04M represent ~0.054% of $5.6B market cap.
- Q1 2026 revenue rose 4.9% YoY to $164.9M; net loss of $31.8M vs net income of $20.5M in Q1 2025.
- 2026 revenue guidance raised to $950M-$1,050M; Lifyorli (relacorilant) approved by FDA for ovarian cancer in March 2026.
Financial Impact
Insider selling of $3.04M is negligible relative to $5.6B market cap.
Risk Factors
- Delays in relacorilant NDA for Cushing's syndrome or regulatory setbacks.
- Competition in ovarian cancer and Cushing's syndrome markets.
- Failure to return to profitability as guided in Q2 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CORT-1778185862573 |
Track record
36 reports on CORT
8 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers